Rofecoxib: new preparation. A disappointing NSAID analgesic.

  title={Rofecoxib: new preparation. A disappointing NSAID analgesic.},
  journal={Prescrire international},
  volume={9 50},
  pages={166-7, 169}
  • Published 2000 in Prescrire international
(1) Rofecoxib, a nonsteroidal antiinflammatory drug, is licensed in France for symptom relief in osteoarthritis. It is promoted by MSD-Chibret as a "specific inhibitor of type 2 cyclooxygenases (COX-2)". (2) The clinical dossier includes trials versus other antiinflammatory drugs, but the reports available are generally vague. Rofecoxib has not been compared with paracetamol. (3) In these trials rofecoxib 12.5-25 mg/day was no more effective than the comparators (ibuprofen or diclofenac) used… CONTINUE READING